Cite
Isolex 300i CD34 - selected cells to support multiple cycles of high-dose therapy.
MLA
Prince, Hm, et al. “Isolex 300i CD34 - Selected Cells to Support Multiple Cycles of High-Dose Therapy.” Cytotherapy (Taylor & Francis Ltd), vol. 4, no. 2, Mar. 2002, pp. 137–45. EBSCOhost, https://doi.org/10.1080/146532402317381848.
APA
Prince, H., Bashford, J., Wall, D., Rischin, D., Parker, N., Toner, G., Seymour, J., Blakey, D., Haylock, D., Simmons, P., Francis, P., Wolf, M., Januszewicz, E., Richardson, G., Scarlett, J., & Briggs, P. (2002). Isolex 300i CD34 - selected cells to support multiple cycles of high-dose therapy. Cytotherapy (Taylor & Francis Ltd), 4(2), 137–145. https://doi.org/10.1080/146532402317381848
Chicago
Prince, Hm, J Bashford, D Wall, D Rischin, N Parker, Gc Toner, Jf Seymour, et al. 2002. “Isolex 300i CD34 - Selected Cells to Support Multiple Cycles of High-Dose Therapy.” Cytotherapy (Taylor & Francis Ltd) 4 (2): 137–45. doi:10.1080/146532402317381848.